Phase II/III Study of WST09 in Prostate Cancer After Radiation Therapy

Phase 3TerminatedNCT00312442

STEBA France16 enrolled

Overview

The aim of this clinical trial is to evaluate the efficacy and safety of the WST09-mediated vascular-targeted photodynamic therapy (VTP) in patients with localized prostate cancer recurrent after external radiation therapy or temporary (High Dose Rate, or HDR) brachytherapy.

This is a multicentre, open labelled, phase II/III, 6-month clinical trial with an additional follow-up at Month 12, aiming to determine the efficacy and tolerability of the WST09-mediated VTP treatment. This treatment consists of an I.V. infusion of WST09 (2 mg/kg), in combination with per-cutaneous interstitial illumination using laser light (wavelength at 763nm) delivered through optical fibres positioned through the perineum in the prostatic lobes. Patients who are eligible to participate in the study must have a clinically diagnosed positive biopsy of the prostate (up to stage T2b-N0-M0) diagnosed after external radiotherapy or temporary brachytherapy (no seeds), and present with increasing PSA levels on three consecutive occasions (at least 3 months apart) post-radiation treatment.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Prostate Cancer

Interventions

Treatment with WST09 Vascular Photodynamic therapyDRUG

Eligibility

Sex: MALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: Histologically proven localized prostate cancer after receiving external radiation therapy; Exclusion Criteria: Patients unwilling or unable to give informed consent; Patients who received or are receiving chemotherapy; Patients previously treated with HIFU, cryotherapy, other salvage treatments, or with a trans-urethral resection of the prostate (TURP); Patients whose previous radiation therapy caused extensive cystitis and/or proctitis. Patients suspected of Disseminated Intravascular Coagulation (DIC). Patients with prior history of coronary artery disease, angina pectoris, myocardial infarction, coronary angioplasty or coronary artery bypass graft, severe valvulopathy, cardiac failure, artrial fibrillation and / or sustained arrhythmia. Patients whose cardiac status does not allow general anesthesia. Patients with history of thromboses or thrombo-embolisms. Patients with history of stroke or transient ischemic attack.

Locations (1)

Princess Margaret Hospital

Toronto, Ontario, Canada

Outcomes

Primary Outcomes

Prostate biopsy results at Month 6 after treatment.

Time frame: 6 months

Secondary Outcomes

Percentage of positive cores in the biopsies prior to and 6 months after the WST09-mediated VTP.

Time frame: 6 months

PSA levels taken periodically for 1 year after the procedure

Time frame: Month 1,3,6 and 1 year

Hypoperfusion according to MRI at Week 1 after the procedure.

Time frame: 1 week and Month 6

Calculated PSA velocity before and after WST09-mediated VTP.

Time frame: Month 1,3,6 and 1 year

Nadir of the PSA after the WST09-mediated VTP compared with the nadir of PSA after radiation therapy

Time frame: Month 1,3,6 and 1 year

To assess the safety and tolerability of WST09-mediated VTP treatment in this patient population

The evaluation of safety will be based on reported adverse events, changes in vital signs and laboratory tests from the Treatment Visit until the study is completed.

Time frame: Day1,Day 7, Month1,3,6,and 12

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.